tct 23: 5y outcomes from the partner 3 low-risk trial
Published 10 months ago • 436 plays • Length 7:43Download video MP4
Download video MP3
Similar videos
-
8:47
tct 23: four-year outcomes from the evolut low risk trial
-
7:09
tct 2021: partner 3: tavr is cost effective compared with savr for low-risk patients
-
3:47
acc 23: tavr in low-risk aortic stenosis patients: 3-year results from the evolut low risk trial
-
7:11
acc 2020: updates from the partner 3 trial — dr michael j mack
-
30:37
view from the thoraxcenter: tct 23 late-breaking science wrap up
-
6:20
tct 23: watch-tavr: watchman for patients with af undergoing tavr
-
4:00
transcatheter aortic valve implantation (tavi)
-
5:51
tavi or keyhole aortic valve replacement: which one is best for you?
-
6:44
tct 23: agent ide: agent paclitaxel coated balloon angioplasty for in-stent restenosis
-
10:28
overview of partner 3 & evolut low risk tavr trials
-
6:06
tct 2022: sentinel® cerebral stroke protection system during transcatheter aortic valve replacement
-
2:35
access points – evolut low risk | acc.23/wcc
-
32:53
will tavr replace low risk savr? (debate 2)
-
12:35
partner 3 what you should know about low risk tavr
-
5:42
acc.24: the smart trial
-
4:01
breaking news: medtronic tavr low-risk clinical trial results released!
-
3:56
partner 3 | tct 2019
-
9:11
live from #acc19: results of the partner 3 trial
-
12:41
partner 3: lessons learned and impact on future patient care
-
5:21
partner 3 trial